Anagliptin

Generic Name
Anagliptin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C19H25N7O2
CAS Number
739366-20-2
Unique Ingredient Identifier
K726J96838
Background

Anagliptin is under investigation for the treatment of LDL Cholesterol, Coronary Disease, Diabetes Mellitus, Glycosylated Hemoglobin, and Dipeptidyl-Peptidase 4 Inhibitors.

Associated Conditions
-
Associated Therapies
-
springermedizin.de
·

Hypoglycemic agents and bone health; an umbrella systematic review of the clinical trials

The article presents a detailed analysis of various studies on the effects of different medications, primarily focusing on fracture risk and other health outcomes. It includes data on the types of medications, their doses, study durations, and the statistical results of their effects on conditions like diabetes, kidney disease, and heart failure. The studies use different methodologies, such as fixed and random effects models, and cover a wide range of drugs including SGLT2 inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists, and others. The results indicate varying levels of effectiveness and safety across different medications and doses, with some showing significant impacts on reducing fracture risk and others demonstrating less conclusive results. The article emphasizes the importance of considering these findings in the context of patient care and treatment decisions.
© Copyright 2024. All Rights Reserved by MedPath